InvestSMART

Oncosil Medical Limited (ASX:OSL)

ALERT: Price-sensitive ASX Announcement for OSL
Current share price for OSL : $1.320 0.52 (65%)+
Announcement
Release
3 Feb 2026 10:53AM
Price at Release
$0.800
Full Release
download
Summary
OncoSil Medical Limited is conducting an equity raising initiative to secure approximately A$8.0 million for expanding its commercial operations and supporting its strategic initiatives. The funds will be raised through institutional placements and an entitlement offer. The OncoSil device, a targeted radiation therapy for pancreatic cancer, is approved for sale in over 34 countries. OncoSil is focusing on expanding market access in Europe and globally, supported by ongoing clinical trials like PANCOSIL and TRIPP-FFX, and new manufacturing investments in Sydney. The device has demonstrated significant improvements in patient outcomes, including increased surgical resection rates and survival times.
Key Points
  • OncoSil Medical Limited is raising approximately A$8.0 million via an equity raising strategy.
  • The capital raising includes a A$3.2 million Tranche 1 Placement and a A$2.8 million Tranche 2 Placement, subject to shareholder approval.
  • A further A$2.0 million will be raised through a non-renounceable entitlement offer.
  • New Shares will have a free attaching option with an exercise price of A$0.90, expiring on 30 June 2027.
  • OncoSil is targeting significant commercial growth in existing European markets.
  • The OncoSil device is approved for sale in over 34 countries.
  • OncoSil aims to expand market access and clinical adoption globally.
  • The company is investing in new manufacturing facilities in Sydney, Australia.
  • OncoSil is involved in pivotal clinical trials, such as the PANCOSIL and TRIPP-FFX studies, to support its market expansion.
  • The device has shown significant efficacy in increasing survival rates and facilitating surgical resections in pancreatic cancer patients.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.